A recent study reported that without modification of N-glycosylation of the IGF-1R at N913, IGF-1R/insulin receptor (IR) heterodimeric receptors would fail to localize to the plasma membrane, thus preventing receptor-ligand binding and decreasing the efficacy of anti-IGF-1R antibody-based cancer therapies. The gene discussed is IGF1R; the disease is cancer.